Can we cure 50% of all multiple myeloma patients in the next five years?
The biology of the plasma cell and drug targets in multiple myeloma
Mechanism of action of proteasome inhibitors
Myeloma 2016: Panel discussion on in vivo drug screening
Caroline Heckman et al.
Myeloma 2016: Panel discussion on the environment biology of myeloma
Dirk Hose et al.